Medtronic’s MiniMed 670G Hybrid Closed Loop Automated Insulin System Receives CE Mark

Medtronic has secured the CE mark of approval to make their MiniMed 670G system available for sale in the European Union. Having previously obtain FDA approval for both adults and pediatric type I diabetes patients, Medtronic is now making the world’s first “Hybrid Closed Loop System” available worldwide. The system uses the latest advancements in diabetes tech to combine an automated insulin pump with a continuous glucose monitor.

“We have seen that this innovation offers great promise for better glucose control and improved quality of life for those living with Type 1 diabetes,” said Pratik Choudhary, M.D., senior lecturer and consultant in diabetes at King’s College London. “The ability of the MiniMed 670G system to stabilize glucose levels automatically is an important advancement, and I look forward to introducing it to my patients in Europe.”

To achieve an accurate fully closed loop system, Medtronic used a new sensor called Guardian 3 (the part of the system that’s inserted just under the skin). The Guardian sensor is 80% smaller than its predecessor, the Enlite, and the battery lasts seven days instead of six, allowing for prolonged, accurate measurement of glucose values. A built-in algorithm, called SmartGuard HCL, helps to guarantee there won’t be glucose spikes. The flexible algorithm enables better diabetes management with reduced user dependency, while also providing smart automation. It all depends on the management needs of the individual patient.

“We’re proud to introduce our most advanced SmartGuard Auto Mode algorithm outside of the United States, which not only helps to prevent lows but works to drive Time in Range – a most important measure of the effect of diabetes management on a patient’s glucose levels – by decreasing time in hyperglycemia,” said Alejandro Galindo, president of the Advanced Insulin Management division within the Diabetes Group at Medtronic. “The MiniMed 670G system advances our ability to automatically suspend and resume insulin delivery to the next level by automating self-adjusting basal insulin delivery every 5 minutes based on sensor glucose values – providing the most advanced algorithm available to deliver leading clinical outcomes.”

Medtronic’s MiniMed 670G system is the a huge milestone toward a fully closed loop system for managing diabetes in a smart, accurate, and most of all, user-friendly way. The 670G system will be available in select countries in Europe in the fall of 2018, subject to local regulatory requirements.